ºÝºÝߣshows by User: ThermoFisher / http://www.slideshare.net/images/logo.gif ºÝºÝߣshows by User: ThermoFisher / Fri, 28 Jun 2019 18:52:41 GMT ºÝºÝߣShare feed for ºÝºÝߣshows by User: ThermoFisher Why you would want a powerful hot-start DNA polymerase for your PCR /slideshow/why-you-would-want-a-powerful-hotstart-dna-polymerase-for-your-pcr/152454538 platinum-ii-taq-accuprime-taq-data-190628185241
Hot-start DNA polymerases are commonly used in PCR for genotyping, sequencing, molecular diagnostics, and high-throughput applications. In this presentation, PCR performance of Invitrogen™ Platinum II Taq Hot-Start DNA Polymerase and Invitrogen™ AccuPrime Taq DNA Polymerase is compared in the following areas: • PCR run time for targets of different lengths • Amplification of AT-rich and GC-rich sequences • Tolerance to PCR inhibitors • Sensitivity in target detection • Universal protocol for PCR targets of different lengths • Multiplex PCR of 15 targets • Product format for direct gel loading Request a sample of Platinum II Taq enzyme at http://bit.ly/2M4U9cw Find other PCR enzymes at http://bit.ly/2JIPrzj Learn more about PCR at http://bit.ly/2y2aSVo #PCR #PCREducation #Invitrogen #InvitrogenSchoolofMolBio ]]>
Hot-start DNA polymerases are commonly used in PCR for genotyping, sequencing, molecular diagnostics, and high-throughput applications. In this presentation, PCR performance of Invitrogen™ Platinum II Taq Hot-Start DNA Polymerase and Invitrogen™ AccuPrime Taq DNA Polymerase is compared in the following areas: • PCR run time for targets of different lengths • Amplification of AT-rich and GC-rich sequences • Tolerance to PCR inhibitors • Sensitivity in target detection • Universal protocol for PCR targets of different lengths • Multiplex PCR of 15 targets • Product format for direct gel loading Request a sample of Platinum II Taq enzyme at http://bit.ly/2M4U9cw Find other PCR enzymes at http://bit.ly/2JIPrzj Learn more about PCR at http://bit.ly/2y2aSVo #PCR #PCREducation #Invitrogen #InvitrogenSchoolofMolBio ]]> Fri, 28 Jun 2019 18:52:41 GMT /slideshow/why-you-would-want-a-powerful-hotstart-dna-polymerase-for-your-pcr/152454538 ThermoFisher@slideshare.net(ThermoFisher) Why you would want a powerful hot-start DNA polymerase for your PCR ThermoFisher Hot-start DNA polymerases are commonly used in PCR for genotyping, sequencing, molecular diagnostics, and high-throughput applications. In this presentation, PCR performance of Invitrogen™ Platinum II Taq Hot-Start DNA Polymerase and Invitrogen™ AccuPrime Taq DNA Polymerase is compared in the following areas: • PCR run time for targets of different lengths • Amplification of AT-rich and GC-rich sequences • Tolerance to PCR inhibitors • Sensitivity in target detection • Universal protocol for PCR targets of different lengths • Multiplex PCR of 15 targets • Product format for direct gel loading Request a sample of Platinum II Taq enzyme at http://bit.ly/2M4U9cw Find other PCR enzymes at http://bit.ly/2JIPrzj Learn more about PCR at http://bit.ly/2y2aSVo #PCR #PCREducation #Invitrogen #InvitrogenSchoolofMolBio <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/platinum-ii-taq-accuprime-taq-data-190628185241-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> Hot-start DNA polymerases are commonly used in PCR for genotyping, sequencing, molecular diagnostics, and high-throughput applications. In this presentation, PCR performance of Invitrogen™ Platinum II Taq Hot-Start DNA Polymerase and Invitrogen™ AccuPrime Taq DNA Polymerase is compared in the following areas: • PCR run time for targets of different lengths • Amplification of AT-rich and GC-rich sequences • Tolerance to PCR inhibitors • Sensitivity in target detection • Universal protocol for PCR targets of different lengths • Multiplex PCR of 15 targets • Product format for direct gel loading Request a sample of Platinum II Taq enzyme at http://bit.ly/2M4U9cw Find other PCR enzymes at http://bit.ly/2JIPrzj Learn more about PCR at http://bit.ly/2y2aSVo #PCR #PCREducation #Invitrogen #InvitrogenSchoolofMolBio
Why you would want a powerful hot-start DNA polymerase for your PCR from Thermo Fisher Scientific
]]> 2192 5 https://cdn.slidesharecdn.com/ss_thumbnails/platinum-ii-taq-accuprime-taq-data-190628185241-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 1 TCRB chain convergence in chronic cytomegalovirus infection and cancer /slideshow/tcrb-chain-convergence-in-chronic-cytomegalovirus-infection-and-cancer/141821795 aacr2019-tcrb-chain-convergence-cytomegalovirus-cancer-poster-190423195739
Human cytomegalovirus (CMV) is a common immune-evasive herpes family virus leading to lifelong asymptomatic infection in 50 to 80% of humans. Current research evaluating the use of TCR sequencing to predict response to immunotherapy has focused on measurements of T cell clonal expansion and TCR convergence (2,3,4) as potential predictive biomarkers for response. Given that CMV infection has been reported to elicit large clonal proliferations of CMV reactive T cells (1), and is a source of chronic antigen stimulation, we hypothesized that CMV infection might alter T cell repertoire features in a manner relevant to the potential biomarker use of TCR sequencing. Here we sought to identify features of CMV infection using TCRB profiling of peripheral blood (PBL) total RNA. We identify reduced T cell evenness and elevated TCR convergence as features of chronic CMV infection.]]>
Human cytomegalovirus (CMV) is a common immune-evasive herpes family virus leading to lifelong asymptomatic infection in 50 to 80% of humans. Current research evaluating the use of TCR sequencing to predict response to immunotherapy has focused on measurements of T cell clonal expansion and TCR convergence (2,3,4) as potential predictive biomarkers for response. Given that CMV infection has been reported to elicit large clonal proliferations of CMV reactive T cells (1), and is a source of chronic antigen stimulation, we hypothesized that CMV infection might alter T cell repertoire features in a manner relevant to the potential biomarker use of TCR sequencing. Here we sought to identify features of CMV infection using TCRB profiling of peripheral blood (PBL) total RNA. We identify reduced T cell evenness and elevated TCR convergence as features of chronic CMV infection.]]> Tue, 23 Apr 2019 19:57:39 GMT /slideshow/tcrb-chain-convergence-in-chronic-cytomegalovirus-infection-and-cancer/141821795 ThermoFisher@slideshare.net(ThermoFisher) TCRB chain convergence in chronic cytomegalovirus infection and cancer ThermoFisher Human cytomegalovirus (CMV) is a common immune-evasive herpes family virus leading to lifelong asymptomatic infection in 50 to 80% of humans. Current research evaluating the use of TCR sequencing to predict response to immunotherapy has focused on measurements of T cell clonal expansion and TCR convergence (2,3,4) as potential predictive biomarkers for response. Given that CMV infection has been reported to elicit large clonal proliferations of CMV reactive T cells (1), and is a source of chronic antigen stimulation, we hypothesized that CMV infection might alter T cell repertoire features in a manner relevant to the potential biomarker use of TCR sequencing. Here we sought to identify features of CMV infection using TCRB profiling of peripheral blood (PBL) total RNA. We identify reduced T cell evenness and elevated TCR convergence as features of chronic CMV infection. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/aacr2019-tcrb-chain-convergence-cytomegalovirus-cancer-poster-190423195739-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> Human cytomegalovirus (CMV) is a common immune-evasive herpes family virus leading to lifelong asymptomatic infection in 50 to 80% of humans. Current research evaluating the use of TCR sequencing to predict response to immunotherapy has focused on measurements of T cell clonal expansion and TCR convergence (2,3,4) as potential predictive biomarkers for response. Given that CMV infection has been reported to elicit large clonal proliferations of CMV reactive T cells (1), and is a source of chronic antigen stimulation, we hypothesized that CMV infection might alter T cell repertoire features in a manner relevant to the potential biomarker use of TCR sequencing. Here we sought to identify features of CMV infection using TCRB profiling of peripheral blood (PBL) total RNA. We identify reduced T cell evenness and elevated TCR convergence as features of chronic CMV infection.
TCRB chain convergence in chronic cytomegalovirus infection and cancer from Thermo Fisher Scientific
]]> 372 4 https://cdn.slidesharecdn.com/ss_thumbnails/aacr2019-tcrb-chain-convergence-cytomegalovirus-cancer-poster-190423195739-thumbnail.jpg?width=120&height=120&fit=bounds document Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 1 Improvement of TMB Measurement by removal of Deaminated Bases in FFPE DNA /slideshow/improvement-of-tmb-measurement-by-removal-of-deaminated-bases-in-ffpe-dna/141821195 aacr2019-tmb-deamination-ffpe-poster-190423195333
Tumor mutational burden (TMB) is a positive predictive factor for response to immune-checkpoint inhibitors in certain types of cancer. The Oncomineâ„¢ Tumor Mutation Load Assay, a targeted next generation sequencing (NGS) assay, measures TMB (from 1.2Mb of coding region) and detects mutations in 409 cancer genes. The TMB values obtained using targeted sequencing are highly correlated with TMB measured by whole exome sequencing. FFPE preservation methods can lead to significant cytosine deamination of the isolated DNA, resulting in decreased sequencing quality. In these samples, uracils are propagated as thymines and result in false C>T substitutions. Analysis of the Oncomineâ„¢ TML Assay using Torrent Suite and Ion Reporter â„¢ software uniquely estimates the degree of deamination in fixed tissues by measuring C:G>T:A variants. This deamination score is used to assess quality of DNA extracted from FFPE tumor tissue. To minimize the influence that excess deamination has on TMB results, we have incorporated a repair treatment to eliminate damaged targets and improve usable TMB values of DNA from damaged FFPE tumor tissue using Uracil-DNA glycosylase (UDG). The Oncomineâ„¢ TML Assay for TMB on the Ion Gene Studioâ„¢ S5 systems in conjunction with a deamination score is informative and potentially predictive for the use of checkpoint inhibitors in multiple cancer types.]]>
Tumor mutational burden (TMB) is a positive predictive factor for response to immune-checkpoint inhibitors in certain types of cancer. The Oncomineâ„¢ Tumor Mutation Load Assay, a targeted next generation sequencing (NGS) assay, measures TMB (from 1.2Mb of coding region) and detects mutations in 409 cancer genes. The TMB values obtained using targeted sequencing are highly correlated with TMB measured by whole exome sequencing. FFPE preservation methods can lead to significant cytosine deamination of the isolated DNA, resulting in decreased sequencing quality. In these samples, uracils are propagated as thymines and result in false C>T substitutions. Analysis of the Oncomineâ„¢ TML Assay using Torrent Suite and Ion Reporter â„¢ software uniquely estimates the degree of deamination in fixed tissues by measuring C:G>T:A variants. This deamination score is used to assess quality of DNA extracted from FFPE tumor tissue. To minimize the influence that excess deamination has on TMB results, we have incorporated a repair treatment to eliminate damaged targets and improve usable TMB values of DNA from damaged FFPE tumor tissue using Uracil-DNA glycosylase (UDG). The Oncomineâ„¢ TML Assay for TMB on the Ion Gene Studioâ„¢ S5 systems in conjunction with a deamination score is informative and potentially predictive for the use of checkpoint inhibitors in multiple cancer types.]]> Tue, 23 Apr 2019 19:53:33 GMT /slideshow/improvement-of-tmb-measurement-by-removal-of-deaminated-bases-in-ffpe-dna/141821195 ThermoFisher@slideshare.net(ThermoFisher) Improvement of TMB Measurement by removal of Deaminated Bases in FFPE DNA ThermoFisher Tumor mutational burden (TMB) is a positive predictive factor for response to immune-checkpoint inhibitors in certain types of cancer. The Oncomineâ„¢ Tumor Mutation Load Assay, a targeted next generation sequencing (NGS) assay, measures TMB (from 1.2Mb of coding region) and detects mutations in 409 cancer genes. The TMB values obtained using targeted sequencing are highly correlated with TMB measured by whole exome sequencing. FFPE preservation methods can lead to significant cytosine deamination of the isolated DNA, resulting in decreased sequencing quality. In these samples, uracils are propagated as thymines and result in false C>T substitutions. Analysis of the Oncomineâ„¢ TML Assay using Torrent Suite and Ion Reporter â„¢ software uniquely estimates the degree of deamination in fixed tissues by measuring C:G>T:A variants. This deamination score is used to assess quality of DNA extracted from FFPE tumor tissue. To minimize the influence that excess deamination has on TMB results, we have incorporated a repair treatment to eliminate damaged targets and improve usable TMB values of DNA from damaged FFPE tumor tissue using Uracil-DNA glycosylase (UDG). The Oncomineâ„¢ TML Assay for TMB on the Ion Gene Studioâ„¢ S5 systems in conjunction with a deamination score is informative and potentially predictive for the use of checkpoint inhibitors in multiple cancer types. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/aacr2019-tmb-deamination-ffpe-poster-190423195333-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> Tumor mutational burden (TMB) is a positive predictive factor for response to immune-checkpoint inhibitors in certain types of cancer. The Oncomineâ„¢ Tumor Mutation Load Assay, a targeted next generation sequencing (NGS) assay, measures TMB (from 1.2Mb of coding region) and detects mutations in 409 cancer genes. The TMB values obtained using targeted sequencing are highly correlated with TMB measured by whole exome sequencing. FFPE preservation methods can lead to significant cytosine deamination of the isolated DNA, resulting in decreased sequencing quality. In these samples, uracils are propagated as thymines and result in false C&gt;T substitutions. Analysis of the Oncomineâ„¢ TML Assay using Torrent Suite and Ion Reporter â„¢ software uniquely estimates the degree of deamination in fixed tissues by measuring C:G&gt;T:A variants. This deamination score is used to assess quality of DNA extracted from FFPE tumor tissue. To minimize the influence that excess deamination has on TMB results, we have incorporated a repair treatment to eliminate damaged targets and improve usable TMB values of DNA from damaged FFPE tumor tissue using Uracil-DNA glycosylase (UDG). The Oncomineâ„¢ TML Assay for TMB on the Ion Gene Studioâ„¢ S5 systems in conjunction with a deamination score is informative and potentially predictive for the use of checkpoint inhibitors in multiple cancer types.
Improvement of TMB Measurement by removal of Deaminated Bases in FFPE DNA from Thermo Fisher Scientific
]]> 657 2 https://cdn.slidesharecdn.com/ss_thumbnails/aacr2019-tmb-deamination-ffpe-poster-190423195333-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 1 What can we learn from oncologists? A survey of molecular testing patterns /ThermoFisher/what-can-we-learn-from-oncologists-a-survey-of-molecular-testing-patterns survey-of-molecular-testing-patterns-poster-181204162601
Oncologists are increasingly incorporating NGS testing to guide targeted and immuno-oncology therapies1. Most clinical NGS testing is confined to large academic institutions and reference labs, despite the fact that most cancer patients are treated in the community settings. We therefore sought to examine molecular testing selection patterns directly from oncologists in order to better identify perceived gaps in testing and treatment paradigms]]>
Oncologists are increasingly incorporating NGS testing to guide targeted and immuno-oncology therapies1. Most clinical NGS testing is confined to large academic institutions and reference labs, despite the fact that most cancer patients are treated in the community settings. We therefore sought to examine molecular testing selection patterns directly from oncologists in order to better identify perceived gaps in testing and treatment paradigms]]> Tue, 04 Dec 2018 16:26:01 GMT /ThermoFisher/what-can-we-learn-from-oncologists-a-survey-of-molecular-testing-patterns ThermoFisher@slideshare.net(ThermoFisher) What can we learn from oncologists? A survey of molecular testing patterns ThermoFisher Oncologists are increasingly incorporating NGS testing to guide targeted and immuno-oncology therapies1. Most clinical NGS testing is confined to large academic institutions and reference labs, despite the fact that most cancer patients are treated in the community settings. We therefore sought to examine molecular testing selection patterns directly from oncologists in order to better identify perceived gaps in testing and treatment paradigms <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/survey-of-molecular-testing-patterns-poster-181204162601-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> Oncologists are increasingly incorporating NGS testing to guide targeted and immuno-oncology therapies1. Most clinical NGS testing is confined to large academic institutions and reference labs, despite the fact that most cancer patients are treated in the community settings. We therefore sought to examine molecular testing selection patterns directly from oncologists in order to better identify perceived gaps in testing and treatment paradigms
What can we learn from oncologists? A survey of molecular testing patterns from Thermo Fisher Scientific
]]> 1687 1 https://cdn.slidesharecdn.com/ss_thumbnails/survey-of-molecular-testing-patterns-poster-181204162601-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 1 Evaluation of ctDNA extraction methods and amplifiable copy number yield using standardized human plasma-based ctDNA control materials /slideshow/evaluation-of-ctdna-extraction-methods-and-amplifiable-copy-number-yield-using-standardized-human-plasmabased-ctdna-control-materials/124937107 ctdna-extraction-method-and-amplifiable-copy-number-yield-poster-181204162217
The use of cell-free circulating tumor DNA (ctDNA) for non-invasive cancer testing has the potential to revolutionize the field. However, emergence of an increasing number of extraction methods and detection assays is rendering laboratory workflow development much more complex and cumbersome. The use of standardized, well characterized ctDNA control materials in human plasma could facilitate the evaluation of extraction efficiency and assay performance across platforms. In this study, we use a full process ctDNA quality control material in true human plasma to demonstrate the variability of extraction yield between different ctDNA extraction kits. We also examine the correlation between the amplifiable copy number and DNA concentration post-extraction.]]>
The use of cell-free circulating tumor DNA (ctDNA) for non-invasive cancer testing has the potential to revolutionize the field. However, emergence of an increasing number of extraction methods and detection assays is rendering laboratory workflow development much more complex and cumbersome. The use of standardized, well characterized ctDNA control materials in human plasma could facilitate the evaluation of extraction efficiency and assay performance across platforms. In this study, we use a full process ctDNA quality control material in true human plasma to demonstrate the variability of extraction yield between different ctDNA extraction kits. We also examine the correlation between the amplifiable copy number and DNA concentration post-extraction.]]> Tue, 04 Dec 2018 16:22:17 GMT /slideshow/evaluation-of-ctdna-extraction-methods-and-amplifiable-copy-number-yield-using-standardized-human-plasmabased-ctdna-control-materials/124937107 ThermoFisher@slideshare.net(ThermoFisher) Evaluation of ctDNA extraction methods and amplifiable copy number yield using standardized human plasma-based ctDNA control materials ThermoFisher The use of cell-free circulating tumor DNA (ctDNA) for non-invasive cancer testing has the potential to revolutionize the field. However, emergence of an increasing number of extraction methods and detection assays is rendering laboratory workflow development much more complex and cumbersome. The use of standardized, well characterized ctDNA control materials in human plasma could facilitate the evaluation of extraction efficiency and assay performance across platforms. In this study, we use a full process ctDNA quality control material in true human plasma to demonstrate the variability of extraction yield between different ctDNA extraction kits. We also examine the correlation between the amplifiable copy number and DNA concentration post-extraction. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/ctdna-extraction-method-and-amplifiable-copy-number-yield-poster-181204162217-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> The use of cell-free circulating tumor DNA (ctDNA) for non-invasive cancer testing has the potential to revolutionize the field. However, emergence of an increasing number of extraction methods and detection assays is rendering laboratory workflow development much more complex and cumbersome. The use of standardized, well characterized ctDNA control materials in human plasma could facilitate the evaluation of extraction efficiency and assay performance across platforms. In this study, we use a full process ctDNA quality control material in true human plasma to demonstrate the variability of extraction yield between different ctDNA extraction kits. We also examine the correlation between the amplifiable copy number and DNA concentration post-extraction.
Evaluation of ctDNA extraction methods and amplifiable copy number yield using standardized human plasma-based ctDNA control materials from Thermo Fisher Scientific
]]> 451 1 https://cdn.slidesharecdn.com/ss_thumbnails/ctdna-extraction-method-and-amplifiable-copy-number-yield-poster-181204162217-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 1 Analytical Validation of the Oncomineâ„¢ Comprehensive Assay v3 with FFPE and Cell Line Tumor Specimens in a CAP-Accredited and CLIA-Certified Clinical Laboratory /slideshow/analytical-validation-of-the-oncomine-comprehensive-assay-v3-with-ffpe-and-cell-line-tumor-specimens-in-a-capaccredited-and-cliacertified-clinical-laboratory/124936873 analytical-validation-of-oncomine-comprehensive-assay-v3-in-clinical-lab-poster-181204162023
Presented here is an analytical validation of OCAv3 at the Life Technologies Clinical Services Laboratory (LTCSL), a CAP-accredited and CLIA-certified clinical laboratory. Analytical validations provide evidence of consistently accurate and relevant sequencing results.]]>
Presented here is an analytical validation of OCAv3 at the Life Technologies Clinical Services Laboratory (LTCSL), a CAP-accredited and CLIA-certified clinical laboratory. Analytical validations provide evidence of consistently accurate and relevant sequencing results.]]> Tue, 04 Dec 2018 16:20:23 GMT /slideshow/analytical-validation-of-the-oncomine-comprehensive-assay-v3-with-ffpe-and-cell-line-tumor-specimens-in-a-capaccredited-and-cliacertified-clinical-laboratory/124936873 ThermoFisher@slideshare.net(ThermoFisher) Analytical Validation of the Oncomineâ„¢ Comprehensive Assay v3 with FFPE and Cell Line Tumor Specimens in a CAP-Accredited and CLIA-Certified Clinical Laboratory ThermoFisher Presented here is an analytical validation of OCAv3 at the Life Technologies Clinical Services Laboratory (LTCSL), a CAP-accredited and CLIA-certified clinical laboratory. Analytical validations provide evidence of consistently accurate and relevant sequencing results. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/analytical-validation-of-oncomine-comprehensive-assay-v3-in-clinical-lab-poster-181204162023-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> Presented here is an analytical validation of OCAv3 at the Life Technologies Clinical Services Laboratory (LTCSL), a CAP-accredited and CLIA-certified clinical laboratory. Analytical validations provide evidence of consistently accurate and relevant sequencing results.
Analytical Validation of the Oncomineâ„¢ Comprehensive Assay v3 with FFPE and Cell Line Tumor Specimens in a CAP-Accredited and CLIA-Certified Clinical Laboratory from Thermo Fisher Scientific
]]> 1694 6 https://cdn.slidesharecdn.com/ss_thumbnails/analytical-validation-of-oncomine-comprehensive-assay-v3-in-clinical-lab-poster-181204162023-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 1 Novel Spatial Multiplex Screening of Uropathogens Associated with Urinary Tract Microbiota Research using a Nanofluidic qPCR Platform /slideshow/novel-spatial-multiplex-screening-of-uropathogens-associated-with-urinary-tract-microbiota-research-using-a-nanofluidic-qpcr-platform/124936564 spatial-multiplex-screening-of-uropathogens-poster-181204161802
Accurate identification of uropathogens in a timely manner is important to correctly understand urinary tract infections(UTI’s), which affects nearly 150 million people each year. The current standard approach for detecting the UTI pathogens is culture based. This method is time consuming, has low throughput, and can lack sensitivity and/or specificity. In addition, not all uropathogens grow equally well under standard culture conditions which can result in a failure to detect the species. To address these gaps, we have developed a unique workflow from sample preparation to target identification using the nanofluidic OpenArray™ platform for spatial multiplexing of target specific assays. In this study, we tested pre-determined blinded research samples and confirmed the subset of results with orthogonal Sanger sequences.]]>
Accurate identification of uropathogens in a timely manner is important to correctly understand urinary tract infections(UTI’s), which affects nearly 150 million people each year. The current standard approach for detecting the UTI pathogens is culture based. This method is time consuming, has low throughput, and can lack sensitivity and/or specificity. In addition, not all uropathogens grow equally well under standard culture conditions which can result in a failure to detect the species. To address these gaps, we have developed a unique workflow from sample preparation to target identification using the nanofluidic OpenArray™ platform for spatial multiplexing of target specific assays. In this study, we tested pre-determined blinded research samples and confirmed the subset of results with orthogonal Sanger sequences.]]> Tue, 04 Dec 2018 16:18:02 GMT /slideshow/novel-spatial-multiplex-screening-of-uropathogens-associated-with-urinary-tract-microbiota-research-using-a-nanofluidic-qpcr-platform/124936564 ThermoFisher@slideshare.net(ThermoFisher) Novel Spatial Multiplex Screening of Uropathogens Associated with Urinary Tract Microbiota Research using a Nanofluidic qPCR Platform ThermoFisher Accurate identification of uropathogens in a timely manner is important to correctly understand urinary tract infections(UTI’s), which affects nearly 150 million people each year. The current standard approach for detecting the UTI pathogens is culture based. This method is time consuming, has low throughput, and can lack sensitivity and/or specificity. In addition, not all uropathogens grow equally well under standard culture conditions which can result in a failure to detect the species. To address these gaps, we have developed a unique workflow from sample preparation to target identification using the nanofluidic OpenArray™ platform for spatial multiplexing of target specific assays. In this study, we tested pre-determined blinded research samples and confirmed the subset of results with orthogonal Sanger sequences. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/spatial-multiplex-screening-of-uropathogens-poster-181204161802-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> Accurate identification of uropathogens in a timely manner is important to correctly understand urinary tract infections(UTI’s), which affects nearly 150 million people each year. The current standard approach for detecting the UTI pathogens is culture based. This method is time consuming, has low throughput, and can lack sensitivity and/or specificity. In addition, not all uropathogens grow equally well under standard culture conditions which can result in a failure to detect the species. To address these gaps, we have developed a unique workflow from sample preparation to target identification using the nanofluidic OpenArray™ platform for spatial multiplexing of target specific assays. In this study, we tested pre-determined blinded research samples and confirmed the subset of results with orthogonal Sanger sequences.
Novel Spatial Multiplex Screening of Uropathogens Associated with Urinary Tract Microbiota Research using a Nanofluidic qPCR Platform from Thermo Fisher Scientific
]]> 207 1 https://cdn.slidesharecdn.com/ss_thumbnails/spatial-multiplex-screening-of-uropathogens-poster-181204161802-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 1 Liquid biopsy quality control – the importance of plasma quality, sample preparation, and library input for next generation sequencing analysis /slideshow/liquid-biopsy-quality-control-the-importance-of-plasma-quality-sample-preparation-and-library-input-for-next-generation-sequencing-analysis/124936233 liquid-biopsy-qc-poster-181204161552
Liquid biopsy is emerging as a non-invasive companion to traditional solid tumor biopsies. As next generation sequencing (NGS) of circulating cell-free nucleic acids (cfNA = cfDNA and cfRNA) becomes common, it’s important to understand the impact of sample preparation on quality, specificity, and sensitivity of liquid biopsy tests. Plasma samples are often limited, and may have undesirable characteristics such as lipemia or hemolysis that contribute unwanted genomic DNA (gDNA) to the sample. Low cfDNA concentration can also limit the amount available for NGS library prep. In this study, we explore the effects of suboptimal plasma and low library input on liquid biopsy NGS, and discuss various techniques for in-process quality control of cfNA samples isolated from plasma]]>
Liquid biopsy is emerging as a non-invasive companion to traditional solid tumor biopsies. As next generation sequencing (NGS) of circulating cell-free nucleic acids (cfNA = cfDNA and cfRNA) becomes common, it’s important to understand the impact of sample preparation on quality, specificity, and sensitivity of liquid biopsy tests. Plasma samples are often limited, and may have undesirable characteristics such as lipemia or hemolysis that contribute unwanted genomic DNA (gDNA) to the sample. Low cfDNA concentration can also limit the amount available for NGS library prep. In this study, we explore the effects of suboptimal plasma and low library input on liquid biopsy NGS, and discuss various techniques for in-process quality control of cfNA samples isolated from plasma]]> Tue, 04 Dec 2018 16:15:52 GMT /slideshow/liquid-biopsy-quality-control-the-importance-of-plasma-quality-sample-preparation-and-library-input-for-next-generation-sequencing-analysis/124936233 ThermoFisher@slideshare.net(ThermoFisher) Liquid biopsy quality control – the importance of plasma quality, sample preparation, and library input for next generation sequencing analysis ThermoFisher Liquid biopsy is emerging as a non-invasive companion to traditional solid tumor biopsies. As next generation sequencing (NGS) of circulating cell-free nucleic acids (cfNA = cfDNA and cfRNA) becomes common, it’s important to understand the impact of sample preparation on quality, specificity, and sensitivity of liquid biopsy tests. Plasma samples are often limited, and may have undesirable characteristics such as lipemia or hemolysis that contribute unwanted genomic DNA (gDNA) to the sample. Low cfDNA concentration can also limit the amount available for NGS library prep. In this study, we explore the effects of suboptimal plasma and low library input on liquid biopsy NGS, and discuss various techniques for in-process quality control of cfNA samples isolated from plasma <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/liquid-biopsy-qc-poster-181204161552-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> Liquid biopsy is emerging as a non-invasive companion to traditional solid tumor biopsies. As next generation sequencing (NGS) of circulating cell-free nucleic acids (cfNA = cfDNA and cfRNA) becomes common, it’s important to understand the impact of sample preparation on quality, specificity, and sensitivity of liquid biopsy tests. Plasma samples are often limited, and may have undesirable characteristics such as lipemia or hemolysis that contribute unwanted genomic DNA (gDNA) to the sample. Low cfDNA concentration can also limit the amount available for NGS library prep. In this study, we explore the effects of suboptimal plasma and low library input on liquid biopsy NGS, and discuss various techniques for in-process quality control of cfNA samples isolated from plasma
Liquid biopsy quality control – the importance of plasma quality, sample preparation, and library input for next generation sequencing analysis from Thermo Fisher Scientific
]]> 1037 1 https://cdn.slidesharecdn.com/ss_thumbnails/liquid-biopsy-qc-poster-181204161552-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 1 Streamlined next generation sequencing assay development using a highly multiplexed FFPE quality control technology based on the Genome in a Bottle /slideshow/streamlined-next-generation-sequencing-assay-development-using-a-highly-multiplexed-ffpe-quality-control-technology-based-on-the-genome-in-a-bottle/124935927 ngs-assay-development-using-highly-multiplexed-ffpe-qc-technology-poster-181204161357
Next generation sequencing (NGS) assay development for solid tumor sequencing requires characterization of variant calling directly from formalin-fixed paraffin embedded (FFPE) tissue samples. However, cell line based FFPE and human FFPE samples only contain 2 to 20 variants, which require laboratories to invest significant resources in sample sourcing and preparation when developing assays to detect 100+ variants]]>
Next generation sequencing (NGS) assay development for solid tumor sequencing requires characterization of variant calling directly from formalin-fixed paraffin embedded (FFPE) tissue samples. However, cell line based FFPE and human FFPE samples only contain 2 to 20 variants, which require laboratories to invest significant resources in sample sourcing and preparation when developing assays to detect 100+ variants]]> Tue, 04 Dec 2018 16:13:57 GMT /slideshow/streamlined-next-generation-sequencing-assay-development-using-a-highly-multiplexed-ffpe-quality-control-technology-based-on-the-genome-in-a-bottle/124935927 ThermoFisher@slideshare.net(ThermoFisher) Streamlined next generation sequencing assay development using a highly multiplexed FFPE quality control technology based on the Genome in a Bottle ThermoFisher Next generation sequencing (NGS) assay development for solid tumor sequencing requires characterization of variant calling directly from formalin-fixed paraffin embedded (FFPE) tissue samples. However, cell line based FFPE and human FFPE samples only contain 2 to 20 variants, which require laboratories to invest significant resources in sample sourcing and preparation when developing assays to detect 100+ variants <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/ngs-assay-development-using-highly-multiplexed-ffpe-qc-technology-poster-181204161357-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> Next generation sequencing (NGS) assay development for solid tumor sequencing requires characterization of variant calling directly from formalin-fixed paraffin embedded (FFPE) tissue samples. However, cell line based FFPE and human FFPE samples only contain 2 to 20 variants, which require laboratories to invest significant resources in sample sourcing and preparation when developing assays to detect 100+ variants
Streamlined next generation sequencing assay development using a highly multiplexed FFPE quality control technology based on the Genome in a Bottle from Thermo Fisher Scientific
]]> 216 4 https://cdn.slidesharecdn.com/ss_thumbnails/ngs-assay-development-using-highly-multiplexed-ffpe-qc-technology-poster-181204161357-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 1 Targeted T-cell receptor beta immune repertoire sequencing in several FFPE tissue types – applications in profiling the tumor microenvironment /slideshow/targeted-tcell-receptor-beta-immune-repertoire-sequencing-in-several-ffpe-tissue-types-applications-in-profiling-the-tumor-microenvironment/124935572 tcr-beta-sequencing-with-ffpe-poster-181204161143
T-cell receptor beta (TCRβ) immune repertoire analysis by next-generation sequencing is a valuable tool for studies of the tumor microenvironment and potential immune responses to cancer immunotherapy. Here we describe a TCRβ sequencing assay that leverages the low sample input requirements of AmpliSeq library preparation technology to extend the capability of targeted immune repertoire sequencing to include FFPE samples which can often be degraded and in short supply]]>
T-cell receptor beta (TCRβ) immune repertoire analysis by next-generation sequencing is a valuable tool for studies of the tumor microenvironment and potential immune responses to cancer immunotherapy. Here we describe a TCRβ sequencing assay that leverages the low sample input requirements of AmpliSeq library preparation technology to extend the capability of targeted immune repertoire sequencing to include FFPE samples which can often be degraded and in short supply]]> Tue, 04 Dec 2018 16:11:43 GMT /slideshow/targeted-tcell-receptor-beta-immune-repertoire-sequencing-in-several-ffpe-tissue-types-applications-in-profiling-the-tumor-microenvironment/124935572 ThermoFisher@slideshare.net(ThermoFisher) Targeted T-cell receptor beta immune repertoire sequencing in several FFPE tissue types – applications in profiling the tumor microenvironment ThermoFisher T-cell receptor beta (TCRβ) immune repertoire analysis by next-generation sequencing is a valuable tool for studies of the tumor microenvironment and potential immune responses to cancer immunotherapy. Here we describe a TCRβ sequencing assay that leverages the low sample input requirements of AmpliSeq library preparation technology to extend the capability of targeted immune repertoire sequencing to include FFPE samples which can often be degraded and in short supply <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/tcr-beta-sequencing-with-ffpe-poster-181204161143-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> T-cell receptor beta (TCRβ) immune repertoire analysis by next-generation sequencing is a valuable tool for studies of the tumor microenvironment and potential immune responses to cancer immunotherapy. Here we describe a TCRβ sequencing assay that leverages the low sample input requirements of AmpliSeq library preparation technology to extend the capability of targeted immune repertoire sequencing to include FFPE samples which can often be degraded and in short supply
Targeted T-cell receptor beta immune repertoire sequencing in several FFPE tissue types – applications in profiling the tumor microenvironment from Thermo Fisher Scientific
]]> 817 3 https://cdn.slidesharecdn.com/ss_thumbnails/tcr-beta-sequencing-with-ffpe-poster-181204161143-thumbnail.jpg?width=120&height=120&fit=bounds document Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 1 Development of Quality Control Materials for Characterization of Comprehensive Next-Generation Sequencing Panels Targeting Cancer Hotspots /slideshow/development-of-quality-control-materials-for-characterization-of-comprehensive-nextgeneration-sequencing-panels-targeting-cancer-hotspots/124935203 qc-materials-cancer-hotspot-panels-poster-181204160931
Targeted next-generation sequencing (NGS) panels can detect hundreds of mutations in key genes using amplification based and hybrid-capture based NGS technologies. Although NGS technology is a powerful tool, optimizing and characterizing test performance on hundreds of variants is extremely challenging, time consuming, and expensive. Samples must be sourced, variants identified and orthogonally confirmed, then quantified and diluted. This effort is then multiplied across dozens of samples, and then samples must be run over many runs and days to assess assay reproducibility, precision, sensitivity, etc. In this study, we developed a novel reference material, experimental design, and analysis pipeline that allows for highly streamlined NGS assay characterization, enabling thorough test characterization across 500+ variants within only 6 runs.]]>
Targeted next-generation sequencing (NGS) panels can detect hundreds of mutations in key genes using amplification based and hybrid-capture based NGS technologies. Although NGS technology is a powerful tool, optimizing and characterizing test performance on hundreds of variants is extremely challenging, time consuming, and expensive. Samples must be sourced, variants identified and orthogonally confirmed, then quantified and diluted. This effort is then multiplied across dozens of samples, and then samples must be run over many runs and days to assess assay reproducibility, precision, sensitivity, etc. In this study, we developed a novel reference material, experimental design, and analysis pipeline that allows for highly streamlined NGS assay characterization, enabling thorough test characterization across 500+ variants within only 6 runs.]]> Tue, 04 Dec 2018 16:09:30 GMT /slideshow/development-of-quality-control-materials-for-characterization-of-comprehensive-nextgeneration-sequencing-panels-targeting-cancer-hotspots/124935203 ThermoFisher@slideshare.net(ThermoFisher) Development of Quality Control Materials for Characterization of Comprehensive Next-Generation Sequencing Panels Targeting Cancer Hotspots ThermoFisher Targeted next-generation sequencing (NGS) panels can detect hundreds of mutations in key genes using amplification based and hybrid-capture based NGS technologies. Although NGS technology is a powerful tool, optimizing and characterizing test performance on hundreds of variants is extremely challenging, time consuming, and expensive. Samples must be sourced, variants identified and orthogonally confirmed, then quantified and diluted. This effort is then multiplied across dozens of samples, and then samples must be run over many runs and days to assess assay reproducibility, precision, sensitivity, etc. In this study, we developed a novel reference material, experimental design, and analysis pipeline that allows for highly streamlined NGS assay characterization, enabling thorough test characterization across 500+ variants within only 6 runs. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/qc-materials-cancer-hotspot-panels-poster-181204160931-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> Targeted next-generation sequencing (NGS) panels can detect hundreds of mutations in key genes using amplification based and hybrid-capture based NGS technologies. Although NGS technology is a powerful tool, optimizing and characterizing test performance on hundreds of variants is extremely challenging, time consuming, and expensive. Samples must be sourced, variants identified and orthogonally confirmed, then quantified and diluted. This effort is then multiplied across dozens of samples, and then samples must be run over many runs and days to assess assay reproducibility, precision, sensitivity, etc. In this study, we developed a novel reference material, experimental design, and analysis pipeline that allows for highly streamlined NGS assay characterization, enabling thorough test characterization across 500+ variants within only 6 runs.
Development of Quality Control Materials for Characterization of Comprehensive Next-Generation Sequencing Panels Targeting Cancer Hotspots from Thermo Fisher Scientific
]]> 212 3 https://cdn.slidesharecdn.com/ss_thumbnails/qc-materials-cancer-hotspot-panels-poster-181204160931-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 1 A High Throughput System for Profiling Respiratory Tract Microbiota /slideshow/a-high-throughput-system-for-profiling-respiratory-tract-microbiota/124934257 high-throughput-system-for-profiling-respiratory-tract-microbiota-poster-181204160347
As one of the leading causes of death globally, respiratory infections could be caused by single or multiple types of viral, bacterial or fungal pathogens that present in the upper and lower respiratory tract. Panel-based testing using molecular methods to identify multiple pathogens simultaneously can contribute to better understanding of respiratory infections.]]>
As one of the leading causes of death globally, respiratory infections could be caused by single or multiple types of viral, bacterial or fungal pathogens that present in the upper and lower respiratory tract. Panel-based testing using molecular methods to identify multiple pathogens simultaneously can contribute to better understanding of respiratory infections.]]> Tue, 04 Dec 2018 16:03:47 GMT /slideshow/a-high-throughput-system-for-profiling-respiratory-tract-microbiota/124934257 ThermoFisher@slideshare.net(ThermoFisher) A High Throughput System for Profiling Respiratory Tract Microbiota ThermoFisher As one of the leading causes of death globally, respiratory infections could be caused by single or multiple types of viral, bacterial or fungal pathogens that present in the upper and lower respiratory tract. Panel-based testing using molecular methods to identify multiple pathogens simultaneously can contribute to better understanding of respiratory infections. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/high-throughput-system-for-profiling-respiratory-tract-microbiota-poster-181204160347-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> As one of the leading causes of death globally, respiratory infections could be caused by single or multiple types of viral, bacterial or fungal pathogens that present in the upper and lower respiratory tract. Panel-based testing using molecular methods to identify multiple pathogens simultaneously can contribute to better understanding of respiratory infections.
A High Throughput System for Profiling Respiratory Tract Microbiota from Thermo Fisher Scientific
]]> 164 1 https://cdn.slidesharecdn.com/ss_thumbnails/high-throughput-system-for-profiling-respiratory-tract-microbiota-poster-181204160347-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 1 A high-throughput approach for multi-omic testing for prostate cancer research /slideshow/a-highthroughput-approach-for-multiomic-testing-for-prostate-cancer-research/124933776 multi-omic-testing-prostate-cancer-research-poster-181204160046
The proliferation of genetic testing technologies and genome-scale studies has increased our understanding of the genetic basis of complex diseases. However, this information alone tells an incomplete story of the underlying biology. Integrative approaches that combine data from multiple sources, such as the genome, transcriptome and/or proteome, can provide a more comprehensive and multi-dimensional model of complex diseases. Similarly, the integration of multiple data types in disease screening can improve our understanding of disease in populations. In a series of groundbreaking multi-omic, population-based studies of prostate cancer, researchers at the Karolinska Institutet in Stockholm, Sweden identified sets of genetic and protein biomarkers that when evaluated together with other clinical research data performed significantly better in predicting cancer risk (1,2) than the most-widely used single protein biomarker, the prostate-specific antigen (PSA).]]>
The proliferation of genetic testing technologies and genome-scale studies has increased our understanding of the genetic basis of complex diseases. However, this information alone tells an incomplete story of the underlying biology. Integrative approaches that combine data from multiple sources, such as the genome, transcriptome and/or proteome, can provide a more comprehensive and multi-dimensional model of complex diseases. Similarly, the integration of multiple data types in disease screening can improve our understanding of disease in populations. In a series of groundbreaking multi-omic, population-based studies of prostate cancer, researchers at the Karolinska Institutet in Stockholm, Sweden identified sets of genetic and protein biomarkers that when evaluated together with other clinical research data performed significantly better in predicting cancer risk (1,2) than the most-widely used single protein biomarker, the prostate-specific antigen (PSA).]]> Tue, 04 Dec 2018 16:00:46 GMT /slideshow/a-highthroughput-approach-for-multiomic-testing-for-prostate-cancer-research/124933776 ThermoFisher@slideshare.net(ThermoFisher) A high-throughput approach for multi-omic testing for prostate cancer research ThermoFisher The proliferation of genetic testing technologies and genome-scale studies has increased our understanding of the genetic basis of complex diseases. However, this information alone tells an incomplete story of the underlying biology. Integrative approaches that combine data from multiple sources, such as the genome, transcriptome and/or proteome, can provide a more comprehensive and multi-dimensional model of complex diseases. Similarly, the integration of multiple data types in disease screening can improve our understanding of disease in populations. In a series of groundbreaking multi-omic, population-based studies of prostate cancer, researchers at the Karolinska Institutet in Stockholm, Sweden identified sets of genetic and protein biomarkers that when evaluated together with other clinical research data performed significantly better in predicting cancer risk (1,2) than the most-widely used single protein biomarker, the prostate-specific antigen (PSA). <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/multi-omic-testing-prostate-cancer-research-poster-181204160046-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> The proliferation of genetic testing technologies and genome-scale studies has increased our understanding of the genetic basis of complex diseases. However, this information alone tells an incomplete story of the underlying biology. Integrative approaches that combine data from multiple sources, such as the genome, transcriptome and/or proteome, can provide a more comprehensive and multi-dimensional model of complex diseases. Similarly, the integration of multiple data types in disease screening can improve our understanding of disease in populations. In a series of groundbreaking multi-omic, population-based studies of prostate cancer, researchers at the Karolinska Institutet in Stockholm, Sweden identified sets of genetic and protein biomarkers that when evaluated together with other clinical research data performed significantly better in predicting cancer risk (1,2) than the most-widely used single protein biomarker, the prostate-specific antigen (PSA).
A high-throughput approach for multi-omic testing for prostate cancer research from Thermo Fisher Scientific
]]> 187 3 https://cdn.slidesharecdn.com/ss_thumbnails/multi-omic-testing-prostate-cancer-research-poster-181204160046-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 1 Why is selecting the right thermal cycler important? /slideshow/why-is-selecting-the-right-thermal-cycler-important/124403624 pg1828-pjt3178-col16997-thermal-cycler-family-customer-facing-deck-global-final-181129165341
Discover the innovations and more that led to amazing discoveries through the use of thermal cyclers. What were scientists able to accomplish? What things are important to them when selecting a thermal cycler? What do you need to advance your science? Learn more about thermal cyclers: http://bit.ly/2Q2oPhF See all thermal cycler offerings: http://bit.ly/2Paf1wH]]>
Discover the innovations and more that led to amazing discoveries through the use of thermal cyclers. What were scientists able to accomplish? What things are important to them when selecting a thermal cycler? What do you need to advance your science? Learn more about thermal cyclers: http://bit.ly/2Q2oPhF See all thermal cycler offerings: http://bit.ly/2Paf1wH]]> Thu, 29 Nov 2018 16:53:41 GMT /slideshow/why-is-selecting-the-right-thermal-cycler-important/124403624 ThermoFisher@slideshare.net(ThermoFisher) Why is selecting the right thermal cycler important? ThermoFisher Discover the innovations and more that led to amazing discoveries through the use of thermal cyclers. What were scientists able to accomplish? What things are important to them when selecting a thermal cycler? What do you need to advance your science? Learn more about thermal cyclers: http://bit.ly/2Q2oPhF See all thermal cycler offerings: http://bit.ly/2Paf1wH <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/pg1828-pjt3178-col16997-thermal-cycler-family-customer-facing-deck-global-final-181129165341-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> Discover the innovations and more that led to amazing discoveries through the use of thermal cyclers. What were scientists able to accomplish? What things are important to them when selecting a thermal cycler? What do you need to advance your science? Learn more about thermal cyclers: http://bit.ly/2Q2oPhF See all thermal cycler offerings: http://bit.ly/2Paf1wH
Why is selecting the right thermal cycler important? from Thermo Fisher Scientific
]]> 1371 6 https://cdn.slidesharecdn.com/ss_thumbnails/pg1828-pjt3178-col16997-thermal-cycler-family-customer-facing-deck-global-final-181129165341-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 1 A rapid library preparation method with custom assay designs for detection of variants at 0.1% allelic frequency in liquid biopsy samples /slideshow/a-rapid-library-preparation-method-with-custom-assay-designs-for-detection-of-variants-at-01-allelic-frequency-in-liquid-biopsy-samples/117849796 ecp-2018-detection-of-variants-with-low-allelic-frequency-in-liquid-biopsy-samples-181002200203
Herein, we describe a new research method for library preparation using the Ion AmpliSeqâ„¢ HD Library Kit with custom assay designs from Ion AmpliSeq HD Panels for detection of low level variants from liquid biopsy samples. This method includes incorporation of molecular tags that enable 0.1% Limit of Detection (LOD) in cell free DNA (cfDNA) and dual barcodes for sample identification. This method is also applicable to formalin-fixed paraffin embedded (FFPE) samples. The libraries can be prepared in as little as 3 hours and are compatible for analysis with the Ion GeneStudioâ„¢ S5 system]]>
Herein, we describe a new research method for library preparation using the Ion AmpliSeqâ„¢ HD Library Kit with custom assay designs from Ion AmpliSeq HD Panels for detection of low level variants from liquid biopsy samples. This method includes incorporation of molecular tags that enable 0.1% Limit of Detection (LOD) in cell free DNA (cfDNA) and dual barcodes for sample identification. This method is also applicable to formalin-fixed paraffin embedded (FFPE) samples. The libraries can be prepared in as little as 3 hours and are compatible for analysis with the Ion GeneStudioâ„¢ S5 system]]> Tue, 02 Oct 2018 20:02:03 GMT /slideshow/a-rapid-library-preparation-method-with-custom-assay-designs-for-detection-of-variants-at-01-allelic-frequency-in-liquid-biopsy-samples/117849796 ThermoFisher@slideshare.net(ThermoFisher) A rapid library preparation method with custom assay designs for detection of variants at 0.1% allelic frequency in liquid biopsy samples ThermoFisher Herein, we describe a new research method for library preparation using the Ion AmpliSeqâ„¢ HD Library Kit with custom assay designs from Ion AmpliSeq HD Panels for detection of low level variants from liquid biopsy samples. This method includes incorporation of molecular tags that enable 0.1% Limit of Detection (LOD) in cell free DNA (cfDNA) and dual barcodes for sample identification. This method is also applicable to formalin-fixed paraffin embedded (FFPE) samples. The libraries can be prepared in as little as 3 hours and are compatible for analysis with the Ion GeneStudioâ„¢ S5 system <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/ecp-2018-detection-of-variants-with-low-allelic-frequency-in-liquid-biopsy-samples-181002200203-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> Herein, we describe a new research method for library preparation using the Ion AmpliSeqâ„¢ HD Library Kit with custom assay designs from Ion AmpliSeq HD Panels for detection of low level variants from liquid biopsy samples. This method includes incorporation of molecular tags that enable 0.1% Limit of Detection (LOD) in cell free DNA (cfDNA) and dual barcodes for sample identification. This method is also applicable to formalin-fixed paraffin embedded (FFPE) samples. The libraries can be prepared in as little as 3 hours and are compatible for analysis with the Ion GeneStudioâ„¢ S5 system
A rapid library preparation method with custom assay designs for detection of variants at 0.1% allelic frequency in liquid biopsy samples from Thermo Fisher Scientific
]]> 450 5 https://cdn.slidesharecdn.com/ss_thumbnails/ecp-2018-detection-of-variants-with-low-allelic-frequency-in-liquid-biopsy-samples-181002200203-thumbnail.jpg?width=120&height=120&fit=bounds document Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 1 Generation of Clonal CRISPR/Cas9-edited Human iPSC Derived Cellular Models and its Applications in Physiologically Relevant Assays /slideshow/generation-of-clonal-crisprcas9edited-human-ipsc-derived-cellular-models-and-its-applications-in-physiologically-relevant-assays/102173860 aacr2018-180612170656
Reprogramming permits the derivation of hiPSCs from diseased patients, and allows us to model diseases in vitro. Furthermore, with the advent of CRISPR mediated genome editing, we can now mimic disease mutations in control hiPSC lines to study the biological effect of just those mutations. hiPSCs can then be differentiated into specified cell types such as neurons which can be used to develop assays for drug safety screening or can be used to model disease phenotypes in a dish to discover new drugs.]]>
Reprogramming permits the derivation of hiPSCs from diseased patients, and allows us to model diseases in vitro. Furthermore, with the advent of CRISPR mediated genome editing, we can now mimic disease mutations in control hiPSC lines to study the biological effect of just those mutations. hiPSCs can then be differentiated into specified cell types such as neurons which can be used to develop assays for drug safety screening or can be used to model disease phenotypes in a dish to discover new drugs.]]> Tue, 12 Jun 2018 17:06:56 GMT /slideshow/generation-of-clonal-crisprcas9edited-human-ipsc-derived-cellular-models-and-its-applications-in-physiologically-relevant-assays/102173860 ThermoFisher@slideshare.net(ThermoFisher) Generation of Clonal CRISPR/Cas9-edited Human iPSC Derived Cellular Models and its Applications in Physiologically Relevant Assays ThermoFisher Reprogramming permits the derivation of hiPSCs from diseased patients, and allows us to model diseases in vitro. Furthermore, with the advent of CRISPR mediated genome editing, we can now mimic disease mutations in control hiPSC lines to study the biological effect of just those mutations. hiPSCs can then be differentiated into specified cell types such as neurons which can be used to develop assays for drug safety screening or can be used to model disease phenotypes in a dish to discover new drugs. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/aacr2018-180612170656-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> Reprogramming permits the derivation of hiPSCs from diseased patients, and allows us to model diseases in vitro. Furthermore, with the advent of CRISPR mediated genome editing, we can now mimic disease mutations in control hiPSC lines to study the biological effect of just those mutations. hiPSCs can then be differentiated into specified cell types such as neurons which can be used to develop assays for drug safety screening or can be used to model disease phenotypes in a dish to discover new drugs.
Generation of Clonal CRISPR/Cas9-edited Human iPSC Derived Cellular Models and its Applications in Physiologically Relevant Assays from Thermo Fisher Scientific
]]> 598 5 https://cdn.slidesharecdn.com/ss_thumbnails/aacr2018-180612170656-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 1 TaqMan®Advanced miRNA cDNA synthesis kit to simultaneously study expression of miRNA and mRNA and detect mutations in serum /slideshow/taqmanadvanced-mirna-cdna-synthesis-kit-to-simultaneously-study-expression-of-mirna-and-mrna-and-detect-mutations-in-serum/102173502 aacr2018-180612170416
MicroRNAs (miRNA) are a class of small non-coding RNAs (approximately 21 nt long) that bind complementary sequences in target mRNAs to specifically regulate gene expression. Aberrant regulation of miRNAs and their targets has been associated with several diseases including cancer. The relationship between miRNA and mRNA has been found to be important in cancer development and progression. Simultaneous expression studies of miRNA and mRNA and detection of mutations in mRNA transcripts can be valuable in understanding molecular mechanisms that have an underlying role in various diseases. We demonstrate the technical verification of a novel method to reverse-transcribe and pre-amplify miRNA and mRNA from sample-limiting serum research samples using the TaqMan® Advanced miRNA cDNA Synthesis Kit. Based on results from previous studies, a signature of 49 mRNA and 37 miRNA targets has been identified that may help distinguish between benign and malignant pancreatic tissues. In this study, these targets and an additional set of transcript mutations were analyzed in serum from normal and test samples. TaqMan assays for miRNA and mRNA targets and custom TaqMan Mutation Detection Assays (TMDAs) were placed on TaqMan Array Cards to facilitate investigation of several samples in a single experiment. Results demonstrate that transcript mutations can be detected and miRNA and mRNA targets can be reliably quantified from a single reverse transcription reaction. For research use only. Not for use in diagnostic purposes.]]>
MicroRNAs (miRNA) are a class of small non-coding RNAs (approximately 21 nt long) that bind complementary sequences in target mRNAs to specifically regulate gene expression. Aberrant regulation of miRNAs and their targets has been associated with several diseases including cancer. The relationship between miRNA and mRNA has been found to be important in cancer development and progression. Simultaneous expression studies of miRNA and mRNA and detection of mutations in mRNA transcripts can be valuable in understanding molecular mechanisms that have an underlying role in various diseases. We demonstrate the technical verification of a novel method to reverse-transcribe and pre-amplify miRNA and mRNA from sample-limiting serum research samples using the TaqMan® Advanced miRNA cDNA Synthesis Kit. Based on results from previous studies, a signature of 49 mRNA and 37 miRNA targets has been identified that may help distinguish between benign and malignant pancreatic tissues. In this study, these targets and an additional set of transcript mutations were analyzed in serum from normal and test samples. TaqMan assays for miRNA and mRNA targets and custom TaqMan Mutation Detection Assays (TMDAs) were placed on TaqMan Array Cards to facilitate investigation of several samples in a single experiment. Results demonstrate that transcript mutations can be detected and miRNA and mRNA targets can be reliably quantified from a single reverse transcription reaction. For research use only. Not for use in diagnostic purposes.]]> Tue, 12 Jun 2018 17:04:16 GMT /slideshow/taqmanadvanced-mirna-cdna-synthesis-kit-to-simultaneously-study-expression-of-mirna-and-mrna-and-detect-mutations-in-serum/102173502 ThermoFisher@slideshare.net(ThermoFisher) TaqMan®Advanced miRNA cDNA synthesis kit to simultaneously study expression of miRNA and mRNA and detect mutations in serum ThermoFisher MicroRNAs (miRNA) are a class of small non-coding RNAs (approximately 21 nt long) that bind complementary sequences in target mRNAs to specifically regulate gene expression. Aberrant regulation of miRNAs and their targets has been associated with several diseases including cancer. The relationship between miRNA and mRNA has been found to be important in cancer development and progression. Simultaneous expression studies of miRNA and mRNA and detection of mutations in mRNA transcripts can be valuable in understanding molecular mechanisms that have an underlying role in various diseases. We demonstrate the technical verification of a novel method to reverse-transcribe and pre-amplify miRNA and mRNA from sample-limiting serum research samples using the TaqMan® Advanced miRNA cDNA Synthesis Kit. Based on results from previous studies, a signature of 49 mRNA and 37 miRNA targets has been identified that may help distinguish between benign and malignant pancreatic tissues. In this study, these targets and an additional set of transcript mutations were analyzed in serum from normal and test samples. TaqMan assays for miRNA and mRNA targets and custom TaqMan Mutation Detection Assays (TMDAs) were placed on TaqMan Array Cards to facilitate investigation of several samples in a single experiment. Results demonstrate that transcript mutations can be detected and miRNA and mRNA targets can be reliably quantified from a single reverse transcription reaction. For research use only. Not for use in diagnostic purposes. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/aacr2018-180612170416-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> MicroRNAs (miRNA) are a class of small non-coding RNAs (approximately 21 nt long) that bind complementary sequences in target mRNAs to specifically regulate gene expression. Aberrant regulation of miRNAs and their targets has been associated with several diseases including cancer. The relationship between miRNA and mRNA has been found to be important in cancer development and progression. Simultaneous expression studies of miRNA and mRNA and detection of mutations in mRNA transcripts can be valuable in understanding molecular mechanisms that have an underlying role in various diseases. We demonstrate the technical verification of a novel method to reverse-transcribe and pre-amplify miRNA and mRNA from sample-limiting serum research samples using the TaqMan® Advanced miRNA cDNA Synthesis Kit. Based on results from previous studies, a signature of 49 mRNA and 37 miRNA targets has been identified that may help distinguish between benign and malignant pancreatic tissues. In this study, these targets and an additional set of transcript mutations were analyzed in serum from normal and test samples. TaqMan assays for miRNA and mRNA targets and custom TaqMan Mutation Detection Assays (TMDAs) were placed on TaqMan Array Cards to facilitate investigation of several samples in a single experiment. Results demonstrate that transcript mutations can be detected and miRNA and mRNA targets can be reliably quantified from a single reverse transcription reaction. For research use only. Not for use in diagnostic purposes.
TaqMan速Advanced miRNA cDNA synthesis kit to simultaneously study expression of miRNA and mRNA and detect mutations in serum from Thermo Fisher Scientific
]]> 1050 7 https://cdn.slidesharecdn.com/ss_thumbnails/aacr2018-180612170416-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 1 Identifying novel and druggable targets in a triple negative breast cancer cell line using the Invitrogenâ„¢ LentiArrayâ„¢ Human Kinase CRISPR Library /slideshow/identifying-novel-and-druggable-targets-in-a-triple-negative-breast-cancer-cell-line-using-the-invitrogen-lentiarray-human-kinase-crispr-library/102172998 aacr2018-180612170006
In this study, we developed a CRISPR/Cas9-based high throughput loss-of-function screen for identifying target genes responsible for the tumor proliferation and growth in TNBC. Our initial focus was to identify essential kinases in MDA-MB-231 cell line using the Invitrogenâ„¢ LentiArrayâ„¢ Human Kinase CRISPR Library, which targets 840 kinases with up to 4 different gRNAs per protein kinase for complete gene knockout. This functional screen identified over 90 protein kinases that are essential for cell viability and cell proliferation. Ten of these hits (CDK1, CDK2, CDK8, CDK10, CDK11A, CDK19, CDK19, CDC7, EPHA2 and WEE1) are well-known targets validated in the literature. Currently, we are in the process validating the novel hits through target gene sequencing, western blotting and target specific small molecule kinase inhibitors.]]>
In this study, we developed a CRISPR/Cas9-based high throughput loss-of-function screen for identifying target genes responsible for the tumor proliferation and growth in TNBC. Our initial focus was to identify essential kinases in MDA-MB-231 cell line using the Invitrogenâ„¢ LentiArrayâ„¢ Human Kinase CRISPR Library, which targets 840 kinases with up to 4 different gRNAs per protein kinase for complete gene knockout. This functional screen identified over 90 protein kinases that are essential for cell viability and cell proliferation. Ten of these hits (CDK1, CDK2, CDK8, CDK10, CDK11A, CDK19, CDK19, CDC7, EPHA2 and WEE1) are well-known targets validated in the literature. Currently, we are in the process validating the novel hits through target gene sequencing, western blotting and target specific small molecule kinase inhibitors.]]> Tue, 12 Jun 2018 17:00:06 GMT /slideshow/identifying-novel-and-druggable-targets-in-a-triple-negative-breast-cancer-cell-line-using-the-invitrogen-lentiarray-human-kinase-crispr-library/102172998 ThermoFisher@slideshare.net(ThermoFisher) Identifying novel and druggable targets in a triple negative breast cancer cell line using the Invitrogenâ„¢ LentiArrayâ„¢ Human Kinase CRISPR Library ThermoFisher In this study, we developed a CRISPR/Cas9-based high throughput loss-of-function screen for identifying target genes responsible for the tumor proliferation and growth in TNBC. Our initial focus was to identify essential kinases in MDA-MB-231 cell line using the Invitrogenâ„¢ LentiArrayâ„¢ Human Kinase CRISPR Library, which targets 840 kinases with up to 4 different gRNAs per protein kinase for complete gene knockout. This functional screen identified over 90 protein kinases that are essential for cell viability and cell proliferation. Ten of these hits (CDK1, CDK2, CDK8, CDK10, CDK11A, CDK19, CDK19, CDC7, EPHA2 and WEE1) are well-known targets validated in the literature. Currently, we are in the process validating the novel hits through target gene sequencing, western blotting and target specific small molecule kinase inhibitors. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/aacr2018-180612170006-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> In this study, we developed a CRISPR/Cas9-based high throughput loss-of-function screen for identifying target genes responsible for the tumor proliferation and growth in TNBC. Our initial focus was to identify essential kinases in MDA-MB-231 cell line using the Invitrogenâ„¢ LentiArrayâ„¢ Human Kinase CRISPR Library, which targets 840 kinases with up to 4 different gRNAs per protein kinase for complete gene knockout. This functional screen identified over 90 protein kinases that are essential for cell viability and cell proliferation. Ten of these hits (CDK1, CDK2, CDK8, CDK10, CDK11A, CDK19, CDK19, CDC7, EPHA2 and WEE1) are well-known targets validated in the literature. Currently, we are in the process validating the novel hits through target gene sequencing, western blotting and target specific small molecule kinase inhibitors.
Identifying novel and druggable targets in a triple negative breast cancer cell line using the Invitrogenâ„¢ LentiArrayâ„¢ Human Kinase CRISPR Library from Thermo Fisher Scientific
]]> 465 8 https://cdn.slidesharecdn.com/ss_thumbnails/aacr2018-180612170006-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 1 Evidence for antigen-driven TCRβ chain convergence in the melanoma-infiltrating T cell repertoire /slideshow/evidence-for-antigendriven-tcr-chain-convergence-in-the-melanomainfiltrating-t-cell-repertoire/102171921 aacr2018-180612165142
T cell convergence refers to the phenomenon whereby antigen-driven selection enriches for T cell receptors (TCRs) having a shared antigen specificity but different amino acid or nucleotide sequence. T cell recruitment and expansion within the tumor microenvironment (TME) may be directed by responses to tumor neoantigen, suggesting that elevated T cell convergence could be a general feature of the tumor infiltrating T cell repertoire. Here we use the Ion AmpliSeq™ Immune Repertoire Assay Plus – TCRβ to evaluate evidence for T cell convergence within melanoma tumor biopsy research samples from a set of 63 subjects plus peripheral blood leukocytes (PBL) from four healthy subjects. We find that the melanoma TME is highly enriched for convergent TCRs compared to healthy donor peripheral blood. We discuss the potential use of TCR convergence as a liquid biopsy compatible predictive biomarker for immunotherapy response.]]>
T cell convergence refers to the phenomenon whereby antigen-driven selection enriches for T cell receptors (TCRs) having a shared antigen specificity but different amino acid or nucleotide sequence. T cell recruitment and expansion within the tumor microenvironment (TME) may be directed by responses to tumor neoantigen, suggesting that elevated T cell convergence could be a general feature of the tumor infiltrating T cell repertoire. Here we use the Ion AmpliSeq™ Immune Repertoire Assay Plus – TCRβ to evaluate evidence for T cell convergence within melanoma tumor biopsy research samples from a set of 63 subjects plus peripheral blood leukocytes (PBL) from four healthy subjects. We find that the melanoma TME is highly enriched for convergent TCRs compared to healthy donor peripheral blood. We discuss the potential use of TCR convergence as a liquid biopsy compatible predictive biomarker for immunotherapy response.]]> Tue, 12 Jun 2018 16:51:42 GMT /slideshow/evidence-for-antigendriven-tcr-chain-convergence-in-the-melanomainfiltrating-t-cell-repertoire/102171921 ThermoFisher@slideshare.net(ThermoFisher) Evidence for antigen-driven TCRβ chain convergence in the melanoma-infiltrating T cell repertoire ThermoFisher T cell convergence refers to the phenomenon whereby antigen-driven selection enriches for T cell receptors (TCRs) having a shared antigen specificity but different amino acid or nucleotide sequence. T cell recruitment and expansion within the tumor microenvironment (TME) may be directed by responses to tumor neoantigen, suggesting that elevated T cell convergence could be a general feature of the tumor infiltrating T cell repertoire. Here we use the Ion AmpliSeq™ Immune Repertoire Assay Plus – TCRβ to evaluate evidence for T cell convergence within melanoma tumor biopsy research samples from a set of 63 subjects plus peripheral blood leukocytes (PBL) from four healthy subjects. We find that the melanoma TME is highly enriched for convergent TCRs compared to healthy donor peripheral blood. We discuss the potential use of TCR convergence as a liquid biopsy compatible predictive biomarker for immunotherapy response. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/aacr2018-180612165142-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> T cell convergence refers to the phenomenon whereby antigen-driven selection enriches for T cell receptors (TCRs) having a shared antigen specificity but different amino acid or nucleotide sequence. T cell recruitment and expansion within the tumor microenvironment (TME) may be directed by responses to tumor neoantigen, suggesting that elevated T cell convergence could be a general feature of the tumor infiltrating T cell repertoire. Here we use the Ion AmpliSeq™ Immune Repertoire Assay Plus – TCRβ to evaluate evidence for T cell convergence within melanoma tumor biopsy research samples from a set of 63 subjects plus peripheral blood leukocytes (PBL) from four healthy subjects. We find that the melanoma TME is highly enriched for convergent TCRs compared to healthy donor peripheral blood. We discuss the potential use of TCR convergence as a liquid biopsy compatible predictive biomarker for immunotherapy response.
Evidence for antigen-driven TCRç¡« chain convergence in the melanoma-infiltrating T cell repertoire from Thermo Fisher Scientific
]]> 274 6 https://cdn.slidesharecdn.com/ss_thumbnails/aacr2018-180612165142-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 1 Analytical performance of a novel next generation sequencing assay for Myeloid cancers /slideshow/analytical-performance-of-a-novel-next-generation-sequencing-assay-for-myeloid-cancers/102171635 aacr2018-180612164933
To support clinical and translational research into precision oncology strategies for myeloid cancers, a next-generation sequencing (NGS) assay was developed to detect common and relevant somatic alterations. To define gene targets that were recurrently altered in myeloid cancers and relevant for clinical and translational research, an extensive survey of investigators at hematology oncology research labs was performed.]]>
To support clinical and translational research into precision oncology strategies for myeloid cancers, a next-generation sequencing (NGS) assay was developed to detect common and relevant somatic alterations. To define gene targets that were recurrently altered in myeloid cancers and relevant for clinical and translational research, an extensive survey of investigators at hematology oncology research labs was performed.]]> Tue, 12 Jun 2018 16:49:33 GMT /slideshow/analytical-performance-of-a-novel-next-generation-sequencing-assay-for-myeloid-cancers/102171635 ThermoFisher@slideshare.net(ThermoFisher) Analytical performance of a novel next generation sequencing assay for Myeloid cancers ThermoFisher To support clinical and translational research into precision oncology strategies for myeloid cancers, a next-generation sequencing (NGS) assay was developed to detect common and relevant somatic alterations. To define gene targets that were recurrently altered in myeloid cancers and relevant for clinical and translational research, an extensive survey of investigators at hematology oncology research labs was performed. <img style="border:1px solid #C3E6D8;float:right;" alt="" src="https://cdn.slidesharecdn.com/ss_thumbnails/aacr2018-180612164933-thumbnail.jpg?width=120&amp;height=120&amp;fit=bounds" /><br> To support clinical and translational research into precision oncology strategies for myeloid cancers, a next-generation sequencing (NGS) assay was developed to detect common and relevant somatic alterations. To define gene targets that were recurrently altered in myeloid cancers and relevant for clinical and translational research, an extensive survey of investigators at hematology oncology research labs was performed.
Analytical performance of a novel next generation sequencing assay for Myeloid cancers from Thermo Fisher Scientific
]]> 549 4 https://cdn.slidesharecdn.com/ss_thumbnails/aacr2018-180612164933-thumbnail.jpg?width=120&height=120&fit=bounds presentation Black http://activitystrea.ms/schema/1.0/post http://activitystrea.ms/schema/1.0/posted 1 https://cdn.slidesharecdn.com/profile-photo-ThermoFisher-48x48.jpg?cb=1632930676 Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, with revenues of more than $20 billion and approximately 65,000 employees globally. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics, deliver medicines to market and increase laboratory productivity. Through our premier brands – Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services – we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive services. www.thermofisher.com https://cdn.slidesharecdn.com/ss_thumbnails/platinum-ii-taq-accuprime-taq-data-190628185241-thumbnail.jpg?width=320&height=320&fit=bounds slideshow/why-you-would-want-a-powerful-hotstart-dna-polymerase-for-your-pcr/152454538 Why you would want a p... https://cdn.slidesharecdn.com/ss_thumbnails/aacr2019-tcrb-chain-convergence-cytomegalovirus-cancer-poster-190423195739-thumbnail.jpg?width=320&height=320&fit=bounds slideshow/tcrb-chain-convergence-in-chronic-cytomegalovirus-infection-and-cancer/141821795 TCRB chain convergence... https://cdn.slidesharecdn.com/ss_thumbnails/aacr2019-tmb-deamination-ffpe-poster-190423195333-thumbnail.jpg?width=320&height=320&fit=bounds slideshow/improvement-of-tmb-measurement-by-removal-of-deaminated-bases-in-ffpe-dna/141821195 Improvement of TMB Mea...